Drugs / Descartes 11
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03994705 | Aug 2019 → May 2021 | plasma cell myeloma | Cartesian Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT04436029 | Feb 2021 → Feb 2022 | plasma cell myeloma | Cartesian Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Descartes-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03994705 ↗ |
| Modality | Cell therapy | “autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor” NCT03994705 ↗ |
| Route | Intravenous | “via intravenous catheter” NCT03994705 ↗ |